Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Trastuzumab monomethyl auristatin F-exatecan derivative conjugate therapeutic - CHO Pharma/TE-Meds; TRZ+4MMAF+4DXd; TRZ-4(MMAF+DXd); TRZ4 MMAF+DXd; TRZ4/MMAF/DXd

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CHO Pharma; TE-Meds
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 19 Apr 2024 Preclinical trials in Breast cancer in USA (Parenteral) prior to April 2024 (TE-Meds pipeline, April 2024)
  • 19 Apr 2024 Pharmacodynamics data from a preclinical trial in Breast cancer released by TE-Meds (TE-Meds pipeline, April 2024)
  • 15 Sep 2023 CHO Pharma and TE-Meds agree to co-develop CHO-TEM antibody drug conjugates
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top